#United States #New York #Levi & Korsinsky #Ultragenyx #Emil Kakkis

Recent Developments in Ultragenyx Pharmaceutical Securities Case

Levi & Korsinsky, LLP, a notable name in securities litigation, is currently directing attention to a securities class action concerning Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). This action suggests significant implications for investors, particularly with respect to leadership accountability and compliance with federal securities laws.

The Context of the Class Action

As outlined by Levi & Korsinsky, the class action involves allegations against upper management at Ultragenyx, specifically targeting Emil D. Kakkis, the company's Founder, President, and CEO, alongside Eric Crombez, the Chief Medical Officer. The details of this lawsuit highlight their potential control over communications that could mislead investors, emphasizing the responsibilities that come with their executive roles.

Allegations of Control Person Liability

The central issue in the lawsuit revolves around Section 20(a) of the Securities Exchange Act, which permits the imposition of liability on individuals who control entities engaged in violations of securities laws. The complaint alleges that Kakkis and Crombez, because of their senior positions, had the power to influence the company’s public assertions, including SEC filings and public statements. Additionally, it is asserted that they were aware of material non-public information, particularly relating to study progress and inherent risks associated with their disclosures.

Sarbanes-Oxley Act Implications

The lawsuit also brings into consideration the Sarbanes-Oxley Act, which mandates rigorous reporting standards for corporate executives. Under this act, individuals in leadership roles are required to certify the accuracy of the information provided in periodic reports to the SEC. It is alleged that Kakkis and Crombez signed such certifications while concealing knowledge that the company's public communications misrepresented critical information. Their actions reflect a potential breach of their duty to ensure that company statements are true and comprehensive.

Investor Participation and Legal Steps

With the class action moving forward, interested investors are urged to act promptly. Those looking to be part of the case must file their claims by April 6, 2026. This is a crucial deadline for individuals who may have incurred losses as a result of the alleged misrepresentations by Ultragenyx’s executive team. Moreover, Levi & Korsinsky stresses the importance of transparency and accountability in corporate communication, particularly in handling sensitive information that affects public trust in the pharmaceutical sector.

Conclusion

The unfolding case highlights the delicate nature of investor relations and the pivotal role that company executives play in ensuring compliance with securities laws. As Ultragenyx Pharmaceutical finds itself in this challenging situation, the ramifications on investor confidence and corporate governance practices are expected to be significant. The action taken by Levi & Korsinsky may not only serve to bring accountability but also strengthen the framework of governance in the life sciences industry moving forward.

For further inquiries and details on participating in the lawsuit, investors can reach out directly to Levi & Korsinsky, LLP via their official contact channels.